Neuroscientific Biopharmaceuticals Ltd has released a press release.
Key Executive Appointments to Support Clinical Studies
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- NSB to investigate treatment for post-COVID Fibrosis
- Strategic Placement to AlphaSwiss Partners
- Appendix 4E and Annual Report
- Updated Appendix 4C
- Full Report from Multiple Sclerosis Study
Later from Neuroscientific Biopharmaceuticals
- Manufacturing Update
- Appendix 4C - quarterly
- Update on Pivotal Ocular Safety Studies
- R&D Tax Rebate Received
- NSB partners with Linear Research for Phase I Clinical Study
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals